Target intelligence / Profile preview

Norovirus major capsid protein VP1 P domain (VP1 P domain)

Target
VP1 P domain
Molecular classification
Viral capsid protein, Viral attachment protein, Lectin-like protein
01

Overview

The Norovirus major capsid protein VP1 P domain is the surface-exposed, protruding region of the virus's primary structural protein. It is functionally divided into the P1 stalk and the P2 head subdomains, with the P2 subdomain containing the critical receptor-binding site for host histo-blood group antigens (HBGAs) (Cao et al., 2007; Tan et al., 2004). This interaction is the first and essential step for viral attachment and entry into the host's intestinal epithelial cells (Koppisetty et al., 2010). As the most distal and variable part of the virion, the P domain is the primary target for neutralizing antibodies and the focus of vaccine development, including virus-like particle (VLP) and P-particle candidates like TAK-214 (NIH, 2022). However, the P2 subdomain undergoes rapid antigenic drift, leading to the emergence of new variants that can escape existing herd immunity (MDPI, 2019). Therapeutic strategies targeting this region include small-molecule HBGA mimics and monoclonal antibodies designed to block the receptor-binding pocket (PubMed, 2016). Understanding the structural plasticity and binding specificity of the P domain is vital for creating broadly protective interventions against norovirus-induced gastroenteritis (bioRxiv, 2024). The domain's ability to form stable dimers and higher-order particles even when isolated makes it a versatile tool for structural biology and vaccine design.

Other names
P domainProtruding domainVP1 P2 subdomainNorovirus attachment proteinVP1 receptor-binding regionP-dimerP-particle
02

Mechanism of action

Blocking the interaction between the viral P2 subdomain and host histo-blood group antigens (HBGAs) to prevent viral attachment and entry into host cells.

03

Biological functions

Viral attachmentHost cell entryReceptor bindingAntigenic variationCapsid assembly
04

Disease associations

GastroenteritisInfection
05

Safety considerations

Antigenic drift leading to immune escapeStrain-specific vaccine efficacyShort duration of natural and vaccine-induced immunity
06

Interacting drugs

TAK-214

4 more in the full profile.

07

Biomarkers

HBGA secretor status (FUT2)Anti-VP1 antibody titersHBGA-blocking antibody titersNorovirus genotype

Beyond the preview

Go deeper on Norovirus major capsid protein VP1 P domain (VP1 P domain).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Norovirus major capsid protein VP1 P domain (VP1 P domain).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call